Mainz Biomed (NASDAQ:MYNZ) Downgraded by HC Wainwright to Neutral

Mainz Biomed (NASDAQ:MYNZ) was downgraded by equities researchers at HC Wainwright from a “buy” rating to a “neutral” rating in a report issued on Monday,Briefing.com Automated Import reports.

Mainz Biomed Price Performance

Mainz Biomed stock opened at $0.21 on Monday. Mainz Biomed has a one year low of $0.19 and a one year high of $1.79. The business has a fifty day moving average of $0.26 and a two-hundred day moving average of $0.40.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.